순번 | 임상시험 제목 | 적응증 | 연구설계 | 의뢰자/실시기관 | 임상단계 | NCT No | 개시일자 |
---|---|---|---|---|---|---|---|
1 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone | AbbVie|Genmab | Phase 3 | 2023-02-08 | |
2 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥0% (MK-3475-D46) | Carcinoma, Non-Small-Cell Lung | Biological: Sacituzumab Govitecan|Biological: Pembrolizumab | Merck Sharp & Dohme LLC|Gilead Sciences | Phase 3 | 2023-02-06 | |
3 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | Erectile Dysfunction Following Radical Prostatectomy|Erectile Dysfunction|Prostate Cancer|Radical Prostatectomy | Drug: BZ371A | Biozeus Biopharmaceutical S.A.|Azidus Brasil Scientific Research and Development Ltda | Phase 1 | 2022-11-16 | |
4 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Carcinoma, Non-small-Cell Lung | Drug: Amivantamab|Drug: Lazertinib|Drug: Carboplatin|Drug: Pemetrexed|Drug: Direct Oral Anticoagulant (DOAC)|Drug: Low Molecular Weight Heparin (LMWH) | Janssen Research & Development, LLC | Phase 2 | 2022-11-11 | |
5 | Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Biological: Tezepelumab|Other: Placebo | AstraZeneca|Amgen | Phase 3 | 2022-11-10 | |
6 | Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency | OTC Deficiency | Genetic: DTX301|Other: Placebo|Drug: Oral Corticosteroids|Drug: Placebo for oral corticosteroids|Drug: Sodium Acetate | Ultragenyx Pharmaceutical Inc | Phase 3 | 2022-10-18 | |
7 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | Hodgkin Lymphoma | Biological: favezelimab/pembrolizumab|Drug: bendamustine|Drug: gemcitabine | Merck Sharp & Dohme LLC | Phase 3 | 2022-10-18 | |
8 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | Drug: Talquetamab|Drug: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone | Janssen Research & Development, LLC | Phase 3 | 2022-10-13 | |
9 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | Follicular Lymphoma (FL) | Drug: Epcoritamab|Drug: Rituximab|Drug: Lenalidomide | AbbVie|Genmab | Phase 3 | 2022-09-20 | |
10 | A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow | SGA, Turner Syndrome, Noonan Syndrome, ISS | Drug: Somapacitan|Drug: Norditropin® | Novo Nordisk A/S | Phase 3 | 2022-08-10 |